For the Quarter Ending June 2025
North America
• Losartan Potassium Price Index in North America moved higher in July 2025 after a period of relative stability in June, driven by stronger restocking trends and tightened regional availability.
• Spot Price in the U.S. market saw upward movement as buyers resumed active procurement following lean offtake in the previous month and firming global supplier offers.
• In April and May 2025, prices moved higher due to reduced import volumes from Asia, coupled with delayed shipments and limited domestic reserves, supporting stronger pricing momentum.
• In June 2025, the Price Index remained mostly stable as excess inventories, weak summer demand from hospitals, and competitive offers from Asian suppliers exerted downward pressure.
• Production Cost Trend stayed moderate in July as upstream input prices stabilized, though increased freight costs and firm Asian supplier quotations contributed to landed cost pressure.
• Demand Outlook improved in July, led by renewed interest from downstream pharmaceutical formulators and distributors preparing for seasonal Q3 consumption cycles.
• Inventory levels began to normalize, with distributors covering short-term gaps as export order fulfillment from Asia became more selective and price-sensitive.
• Export competitiveness of Asian suppliers decreased slightly in July, giving U.S. buyers less room to negotiate and pushing them to accept higher offer levels to secure supply.
• Price Forecast for Q3 2025 is bullish, as tighter global supply, improving regional demand, and rising restocking interest are expected to sustain upward price pressure through the quarter.
• Why did the price change in July 2025? Prices increased due to a combination of rising procurement from downstream drug manufacturers, limited spot supply availability, and reduced pricing flexibility from key Asian exporters.
Europe
• Losartan Potassium Price Index in Europe showed an upward trend in July 2025, supported by increased procurement activity and tighter regional availability.
• Spot Price for Losartan Potassium in Germany rose as downstream pharmaceutical buyers intensified restocking efforts ahead of the Q3 demand cycle.
• In June 2025, the Losartan Potassium Price Index had declined amid high inventory levels and sluggish institutional demand across Western Europe.
• Production Cost Trend for Losartan Potassium remained steady, though minor increases in shipping costs and regulatory compliance slightly impacted landed costs.
• The Demand Outlook improved in July 2025, driven by preparations for seasonal surges in antihypertensive drug consumption and renewed purchases from public and private healthcare channels.
• Supply constraints from Asia, particularly China and India, reduced the availability of bulk Losartan Potassium shipments, contributing to firm regional pricing.
• Wholesalers in Germany reported leaner safety stocks and adopted short-term contracts at higher rates, supporting stronger market sentiment.
• The market also witnessed more frequent spot inquiries as formulation plants sought to secure forward coverage amid rising freight and regulatory headwinds.
• Price Forecast for Q3 2025 suggests continued upward momentum, underpinned by strong demand expectations and export limitations from major API-producing nations.
• Why did the price change in July 2025? Losartan Potassium prices increased due to restocking by pharmaceutical buyers in Germany, limited exports from Asian suppliers, and improving demand prospects for Q3.
APAC
• Price Index for Losartan Potassium in APAC (China) witnessed an upward adjustment in July 2025, reversing the softening trend from June and driven by restocking activity and rising trade interest.
• Spot Price for Losartan Potassium (USP) FOB Zhejiang (China) rose in July 2025 compared to June levels of USD 52,900/MT, reflecting stronger procurement and recovering global offtake.
• In April 2025, prices rose by 0.62% due to front-loaded exports ahead of US tariff changes, reduced production activity, and limited inventory, which kept market supply tight and prices firm.
• In May 2025, prices jumped by 9.28% as supply remained constrained amid rising demand, early-month production shutdowns, and renewed US buying interest following eased trade tariffs.
• In June 2025, prices corrected downward by 0.19% due to elevated inventory levels, weak overseas orders, and falling input costs, which created pressure on suppliers to lower prices.
• Production Cost Trend in July 2025 shifted upward slightly, influenced by firmer raw material prices and moderate increases in manufacturing utility expenses compared to June.
• Demand Outlook improved, supported by renewed buying activity from Southeast Asian countries and moderate recovery in overseas inquiries, particularly from the US and EU pharmaceutical sectors.
• Export competitiveness also strengthened slightly, as freight volatility stabilized and buyer sentiment improved due to easing cost pressures and anticipation of Q3 procurement cycles.
• Inventory dynamics saw partial clearing at the supplier level due to active order placement early in the month, although stock levels remained above seasonal averages by end-July.
• Price Forecast for August 2025 indicates a potential further increase, as downstream pharmaceutical restocking in APAC and global trade stabilization are expected to support firmer prices.
• Why did the price change in July 2025? Prices increased due to renewed export activity, improved international buying sentiment, and supplier efforts to push up offers amid stabilizing inventory and raw material cost uptick.
For the Quarter Ending March 2025
North America
The U.S. Losartan Potassium market experienced fluctuating price movements throughout Q1 2025, influenced by varying supply conditions, shifting demand, and evolving economic factors. In January, prices saw a slight uptick, supported by steady demand from the pharmaceutical sector and relatively stable supply conditions. Importers strategically managed their inventories to accommodate consistent levels of demand, which helped maintain a balanced market despite ongoing challenges related to freight logistics and slight supply constraints.
By February, the market shifted, with prices fluctuating due to tighter supply conditions and rising production costs. The implementation of a 10% tariff on Chinese imports compounded the situation, leading to elevated procurement expenses. This, coupled with logistical delays and a reduction in available inventory, intensified competition among buyers, pushing the market into a period of volatility. At the same time, moderate demand from the healthcare sector continued to support the market, though overall trading activity remained more cautious amid rising costs and uncertainty in trade relations.
In March, the market saw further fluctuations, with prices remaining sensitive to the ongoing supply-side constraints and raw material cost increases. The persistent trade-related challenges, including the 10% tariff and retaliatory measures, continued to exert upward pressure on procurement costs. While logistical costs began to ease slightly, the overall market sentiment remained cautious as buyers adopted a more conservative procurement approach. Demand from the pharmaceutical sector remained relatively stable, helping to support prices, but overall market conditions remained fluid due to external factors such as the evolving trade situation.
Throughout Q1 2025, the U.S. Losartan Potassium market experienced fluctuating prices, influenced by a combination of steady demand, supply-side constraints, and rising production costs. The 10% tariff and ongoing trade uncertainties played a significant role in shaping procurement strategies, adding complexity to the market dynamics. Despite fluctuations, the market ended the quarter with relatively stable fundamentals, driven by consistent demand from the healthcare sector and supply chain challenges.
Asia Pacific
In January 2025, Losartan Potassium prices in China experienced a decline, primarily driven by weak demand, oversupply, and unfavorable export conditions. A sluggish pharmaceutical and healthcare sector, coupled with an excess of stock, exerted downward pressure on prices. Consumer hesitancy, influenced by low inflation and the anticipation of further price reductions, also dampened demand. Additionally, many buyers had already stocked up ahead of the Lunar New Year, leading to subdued market activity. The strengthening of the Chinese yuan further compounded the situation, making exports more expensive for international buyers. In response, manufacturers reduced production and resorted to discounting existing stock to stimulate sales, continuing the downward price trend.
In February 2025, Losartan Potassium prices saw a further reduction, driven by lower freight costs, weak demand, and uncertain trade tariffs. Reduced logistics expenses made it more cost-effective for manufacturers to transport goods, contributing to price cuts. Meanwhile, weak domestic and international demand, coupled with excess inventory, intensified competition among suppliers, who offered discounts to clear stock. The imposition of a 10% tariff by the U.S. on Chinese products added uncertainty, leading to a slowdown in export orders and exacerbating the overall price decline.
However, in March 2025, the market saw a modest recovery with a 0.42% price increase. Tightened supply conditions, driven by inventory drawdowns and stronger demand from the pharmaceutical sector, helped support the price uptick. Additionally, heightened trade uncertainty, particularly due to new U.S. tariffs, prompted international buyers to accelerate procurement, further pressuring supply chains. Rising manufacturing activity and increased input costs contributed to upward pricing momentum, while steady demand from both domestic and export markets reinforced the price stability during the month.
Europe
In Q1 2025, the German Losartan Potassium market experienced fluctuating prices, driven by a balance of supply-side pressures, demand from the pharmaceutical sector, and global economic factors. January began with a slight price uptick, as German buyers maintained stable procurement in anticipation of potential supply disruptions due to the Lunar New Year holiday. While demand remained steady from key pharmaceutical buyers, the market was influenced by logistical constraints, particularly in the transportation of bulk pharmaceutical goods. These factors provided upward momentum to the market, although overall price movements remained moderate.
By February, the market saw a shift, with prices reflecting a combination of high procurement costs and constrained supply. The depreciation of the Euro against the U.S. Dollar contributed to higher import expenses, which impacted the overall price trend. Additionally, reduced inventory levels and higher input costs from major exporting countries, including China, further compounded pricing pressure. Despite some relief from lower freight rates, demand from the pharmaceutical and healthcare sectors remained strong, supporting a resilient price structure. However, softer demand from some downstream industries moderated the price trajectory, leading to more volatility in February.
In March, prices fluctuated again, with market conditions remaining sensitive to the dynamics of supply and demand. Rising production costs in key regions and the persistent volatility of the Euro continued to exert upward pressure on procurement expenses. However, stronger industrial activity, reflected in Germany’s Manufacturing PMI, supported demand from pharmaceutical and nutraceutical sectors. These factors, combined with logistical improvements and a more favorable freight market, helped balance the supply-demand equation, although prices remained responsive to global market conditions.
Throughout Q1 2025, the German Losartan Potassium market experienced a series of fluctuating prices, driven by a mix of steady demand from the pharmaceutical sector, cost pressures from global supply chains, and currency volatility. Although there were periods of upward momentum due to procurement challenges and rising production costs, the market also faced periods of softer demand and cost relief from logistics, leading to a fluctuating yet generally stable pricing environment across the quarter.
For the Quarter Ending December 2024
North America
In Q4 2024, Losartan Potassium prices in the USA experienced notable fluctuations due to evolving market conditions. October saw a slight price increase, driven by rising demand following Federal Reserve rate cuts that helped boost consumer confidence. Supply chain disruptions—such as extended port congestion, labor strikes, and concerns over potential tariff hikes under President-elect Donald Trump—further strained supply and demand, driving prices up.
However, by November, prices began to soften as demand weakened under the pressure of inflation and high interest rates. The U.S. dollar’s appreciation reduced import costs, and the resolution of the ILA strike eased logistical bottlenecks. Coupled with strong inventories, these factors allowed suppliers to lower prices, providing relief to consumers.
In December, the downward trend continued, fueled by declining consumer confidence, slower seasonal demand, and proactive inventory stocking ahead of anticipated January strikes and the Chinese Lunar New Year. Inflation concerns and tariff uncertainties led to more cautious purchasing behavior, while abundant supply and aggressive pricing strategies by suppliers exerted additional downward pressure on prices. Overall, Q4 2024 saw a volatile yet declining market trajectory for Losartan Potassium.
Asia Pacific
In the fourth quarter of 2024, the Losartan Potassium market in China exhibited a fluctuating pricing pattern, influenced by various economic and market dynamics. In October, prices saw a modest increase, driven by a recovery in China's manufacturing sector, which was bolstered by government stimulus efforts. Enhanced domestic and export demand, fueled by monetary easing and a weaker yuan, spurred consumer confidence and external orders, enabling suppliers to hike prices.
However, by November, this upward momentum reversed. High inventory levels, declining domestic demand, and weak international orders—especially from the USA and Europe—led to an oversupply situation. Meanwhile, falling crude oil prices reduced production costs, encouraging manufacturers to cut prices in order to stay competitive.
In December, the downward trend continued as consumer demand remained weak amidst ongoing disinflation in China. Adjusted procurement strategies by both pharmaceutical companies and international buyers further dampened demand. The holiday season's reduced foreign orders left suppliers with excess stock, prompting additional price reductions as they aimed to clear inventories before the year's end. Overall, Q4 2024 showcased a transition from early price increases to subsequent declines, driven by shifts in demand and changing market conditions.
Europe
In Q4 2024, Losartan Potassium prices in Germany followed a fluctuating pattern, influenced by changing market conditions throughout the quarter. October saw a moderate price increase, driven by a boost in business sentiment fueled by optimism over economic recovery and the European Central Bank's third interest rate cut to 3.25%. This monetary easing spurred spending and investment, while supply chain disruptions at Hamburg’s ports, along with proactive inventory stocking, added upward pressure on prices.
However, in November, the trend reversed as demand from end-sectors weakened and inflationary pressures eased, leading to price declines. A notable drop in consumer spending and retail activity, coupled with a 1.9% decrease in energy costs, reduced production expenses, which allowed suppliers to lower prices and remain competitive.
The downward trend continued into December, with subdued demand from key sectors and cautious purchasing behavior, driven by lingering inflation concerns. The depreciation of the euro further increased import costs, while high inventory levels and year-end clearance strategies put additional downward pressure on prices. Additionally, severe winter weather disrupted logistics and dampened consumer activity. Overall, Q4 2024 marked a shift from early optimism to a more cautious economic outlook, contributing to a volatile yet declining pricing environment for Losartan Potassium.
For the Quarter Ending September 2024
North America
In Q3 2024, Losartan Potassium prices in North America exhibited a mixed trajectory, shaped by a variety of market dynamics. The quarter commenced with a price increase in July, fueled by heightened consumer optimism regarding business conditions. This positive sentiment created an encouraging environment for pricing, supported by strong demand for Losartan Potassium. Additionally, supply chain disruptions played a significant role, as blank sailings forced ships to reroute via the Cape of Good Hope due to severe port congestion in both Asia and North America. These logistical challenges further tightened the market, contributing to the upward price movement.
However, this upward trend did not persist. By August, prices began to decline, influenced by an improved outlook on inflation. The easing of inflationary pressures led to a significant drop in import prices, marking the largest decrease in eight months. This reduction in import costs, combined with only modest increases in producer and consumer prices, alleviated the pressure on Losartan Potassium pricing.
Despite the initial decline, the market experienced a rebound by the end of September. This resurgence in prices was driven by a renewed sense of consumer confidence, which translated into increased demand for Losartan Potassium. As consumer sentiments improved, they exerted upward pressure on prices, reversing the previous downward trend.
Asia Pacific
In Q3 2024, the pricing landscape for Losartan Potassium in the APAC region displayed a mixed trajectory, significantly influenced by a variety of market dynamics. The quarter began with a notable surge in prices, primarily driven by strong global demand. This demand was particularly robust due to heightened export activities from Asia to key markets, including North America and Europe. Foreign importers were proactive during this period, placing larger orders as a precautionary measure against potential shortages, which further bolstered demand and contributed to upward price momentum. However, the situation shifted by August, as prices began to experience a significant decline. This downturn was largely attributed to weakening demand, highlighted by sluggish export activity that indicated a broader loss of economic momentum within the region. As the market grappled with these challenges, improved supply conditions eased some of the previously established upward pressure on prices, leading to a noticeable drop. As the quarter progressed into September, the market saw a rebound in prices, fueled by a resurgence in domestic demand and an increase in new orders. Market participants quickly adapted their strategies to capitalize on these improved conditions, which contributed to a price recovery toward the end of the quarter. The renewed optimism in the market was reflected in a more active buying environment, signaling a shift back to a more favorable pricing scenario.
Europe
In Q3 2024, the pricing of Losartan Potassium in Europe exhibited a mixed trajectory, influenced by a range of significant market forces. Initially, the quarter commenced with an upward trend in prices, driven by a robust surge in demand for the pharmaceutical. This demand was bolstered by strong consumer sentiment and a general sense of economic optimism across the region. Supply chain disruptions, particularly affecting key shipping routes, further constrained the availability of Losartan Potassium, adding upward pressure on prices as logistical challenges hindered timely deliveries. However, as the quarter progressed into mid-Q3, the pricing landscape shifted. Prices began to decline, primarily due to deteriorating economic conditions in Germany, where business morale fell for the third consecutive month. This ongoing economic struggle dampened recovery prospects and reduced overall demand for Losartan Potassium, resulting in softer pricing during this period. Despite the mid-quarter downturn, the market saw a rebound toward the end of Q3. This resurgence was spurred by a recovery in consumer sentiment across Europe, reflecting improved income expectations and an increased willingness to spend among consumers. The easing of inflationary pressures also played a critical role, alleviating financial constraints and further supporting the uptick in prices.
FAQ’s
1. Why did Losartan Potassium prices rise in the APAC region during July 2025?
Losartan Potassium prices in APAC rose due to tightening inventories, a rebound in overseas demand, and improved export competitiveness, particularly from China. The weakening of the Yuan and modest recovery in inquiries from Western markets also contributed to the upward Price Index movement.
2. What drove the Losartan Potassium Price Index upward in North America in July 2025?
In North America, the Price Index increased as downstream pharmaceutical companies stepped up restocking and accepted higher Spot Prices amid slower import arrivals from APAC and firmer freight costs. The Demand Outlook improved as formulators anticipated supply disruptions in Q3 2025.
3. Why did the price change in July 2025 in the European Losartan Potassium market?
The price increased in Europe due to reduced export volumes from Asia, stronger restocking by German pharmaceutical firms, and improved demand ahead of the Q3 consumption cycle. Stable Production Cost Trends combined with tighter API availability supported higher prices.
4. What is the Price Forecast for Q3 2025 for Losartan Potassium in major regions?
The Price Forecast for Q3 2025 across APAC, North America, and Europe indicates a stable-to-firm trend, supported by restocking, steady demand, and constrained global API supply. Regulatory bottlenecks and costlier logistics are also expected to uphold elevated pricing.
5. How are production and inventory dynamics influencing Losartan Potassium prices globally?
Global prices are being influenced by cautious production schedules in Asia, lean inventories across North America and Europe, and heightened restocking needs. The Production Cost Trend has remained steady, but reduced supplier output and long lead times are supporting firmer Spot Prices in all three regions.
